Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > My, my.....Ithno and Ionc working overtime to trash Oncy....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(86)
•••
Comment by Quentin30on Nov 28, 2023 1:55pm
105 Views
Post# 35756792

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:My, my.....Ithno and Ionc working overtime to trash Oncy....

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:My, my.....Ithno and Ionc working overtime to trash Oncy....The cost of treatment may be large, but the cost of hospitalisation over the lifetime of each patient gets removed.

For some monogeneic diseases if a patient costs $1m per year to the payer, then I think they would happily pay multiples of that for a one and done therapy, and paitents will be asking for cures. There's an ethical angle here also.

So the treatment may at first appear expensive, but in the long run it's more cost effective. Their pipeline is very healthy, and if they hit two home runs, then today's price will be history. With over 2 billion in cash and a revenue stream about to start, then I see no dilution here...

And thanks, I'll take those profits, and may come back to ONCY around April next year. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities